APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bispecific Antibodies for Cancer

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Bispecific Antibodies for Cancer Industry Growth and Trends Forecast to 2032

20 December 202592 pages

Choose your research edition.

Industry ResearchBispecific Antibodies for Cancer Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Bispecific Antibodies for Cancer Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Bispecific Antibodies for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bispecific Antibodies for Cancer Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Bispecific Antibodies for Cancer Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Bispecific Antibodies for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Bispecific Antibodies for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Bispecific Antibodies for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bispecific Antibodies for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Bispecific Antibodies for Cancer include Ben Kang Biopharmaceutical (Shenzhen), Astella Pharma, Amgen, Regeneron Pharmaceuticals and Merus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Bispecific Antibodies for Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Bispecific Antibodies for Cancer market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Bispecific Antibodies for Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Bispecific Antibodies for Cancer.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Bispecific Antibodies for Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Bispecific Antibodies for Cancer Market by Company

Ben Kang Biopharmaceutical (Shenzhen)

Astella Pharma

Amgen

Regeneron Pharmaceuticals

Merus

Bispecific Antibodies for Cancer Segment by Type

CD19/CD3

CD30/CD16A

Bispecific Antibodies for Cancer Segment by Application

Hospital

Pharmaceutical Companies

Other

Bispecific Antibodies for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bispecific Antibodies for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bispecific Antibodies for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bispecific Antibodies for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Bispecific Antibodies for Cancer manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Bispecific Antibodies for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CD19/CD3 Table 2. Major Company of CD30/CD16A Table 3. Global Bispecific Antibodies for Cancer Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (k units) Table 5. Global Bispecific Antibodies for Cancer Sales Market Share in Volume by Type (2021-2026) Table 6. Global Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (US$ Million) Table 7. Global Bispecific Antibodies for Cancer Sales Market Share in Value by Type (2021-2026) Table 8. Global Bispecific Antibodies for Cancer Price by Type (2021-2026) & (US$/unit) Table 9. Global Bispecific Antibodies for Cancer Sales by Type (2027-2032) & (k units) Table 10. Global Bispecific Antibodies for Cancer Sales Market Share in Volume by Type (2027-2032) Table 11. Global Bispecific Antibodies for Cancer Sales by Type (2027-2032) & (US$ Million) Table 12. Global Bispecific Antibodies for Cancer Sales Market Share in Value by Type (2027-2032) Table 13. Global Bispecific Antibodies for Cancer Price by Type (2027-2032) & (US$/unit) Table 14. North America Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (k units) Table 15. North America Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (k units) Table 17. Europe Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (k units) Table 21. Latin America Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Bispecific Antibodies for Cancer Sales by Type (2021-2026) & (US$ Million) Table 24. Bispecific Antibodies for Cancer Industry Trends Table 25. Bispecific Antibodies for Cancer Industry Drivers Table 26. Bispecific Antibodies for Cancer Industry Opportunities and Challenges Table 27. Bispecific Antibodies for Cancer Industry Restraints Table 28. Global Bispecific Antibodies for Cancer Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Bispecific Antibodies for Cancer Revenue Market Share by Company (2021-2026) Table 30. Global Bispecific Antibodies for Cancer Sales by Company (2021-2026) & (k units) Table 31. Global Bispecific Antibodies for Cancer Sales Share by Company (2021-2026) Table 32. Global Bispecific Antibodies for Cancer Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Bispecific Antibodies for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Bispecific Antibodies for Cancer Major Company Production Sites and Headquarters Table 35. Global Bispecific Antibodies for Cancer Company, Product Type & Application Table 36. Global Bispecific Antibodies for Cancer Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Bispecific Antibodies for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Bispecific Antibodies for Cancer Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Bispecific Antibodies for Cancer Sales by Region (2021-2026) & (k units) Table 41. Global Bispecific Antibodies for Cancer Sales Market Share in Volume by Region (2021-2026) Table 42. Global Bispecific Antibodies for Cancer Sales by Region (2021-2026) & (US$ Million) Table 43. Global Bispecific Antibodies for Cancer Sales Market Share in Value by Region (2021-2026) Table 44. Global Bispecific Antibodies for Cancer Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Bispecific Antibodies for Cancer Sales by Region (2027-2032) & (k units) Table 46. Global Bispecific Antibodies for Cancer Sales Market Share in Volume by Region (2027-2032) Table 47. Global Bispecific Antibodies for Cancer Sales by Region (2027-2032) & (US$ Million) Table 48. Global Bispecific Antibodies for Cancer Sales Market Share in Value by Region (2027-2032) Table 49. Global Bispecific Antibodies for Cancer Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Bispecific Antibodies for Cancer Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (k units) Table 52. Global Bispecific Antibodies for Cancer Sales Market Share in Volume by Application (2021-2026) Table 53. Global Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (US$ Million) Table 54. Global Bispecific Antibodies for Cancer Sales Market Share in Value by Application (2021-2026) Table 55. Global Bispecific Antibodies for Cancer Price by Application (2021-2026) & (US$/unit) Table 56. Global Bispecific Antibodies for Cancer Sales by Application (2027-2032) & (k units) Table 57. Global Bispecific Antibodies for Cancer Sales Market Share in Volume by Application (2027-2032) Table 58. Global Bispecific Antibodies for Cancer Sales by Application (2027-2032) & (US$ Million) Table 59. Global Bispecific Antibodies for Cancer Sales Market Share in Value by Application (2027-2032) Table 60. Global Bispecific Antibodies for Cancer Price by Application (2027-2032) & (US$/unit) Table 61. North America Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (k units) Table 62. North America Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (k units) Table 64. Europe Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (k units) Table 68. Latin America Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Bispecific Antibodies for Cancer Sales by Application (2021-2026) & (US$ Million) Table 71. Ben Kang Biopharmaceutical (Shenzhen) Company Information Table 72. Ben Kang Biopharmaceutical (Shenzhen) Business Overview Table 73. Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Product Portfolio Table 75. Ben Kang Biopharmaceutical (Shenzhen) Recent Development Table 76. Astella Pharma Company Information Table 77. Astella Pharma Business Overview Table 78. Astella Pharma Bispecific Antibodies for Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Astella Pharma Bispecific Antibodies for Cancer Product Portfolio Table 80. Astella Pharma Recent Development Table 81. Amgen Company Information Table 82. Amgen Business Overview Table 83. Amgen Bispecific Antibodies for Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Amgen Bispecific Antibodies for Cancer Product Portfolio Table 85. Amgen Recent Development Table 86. Regeneron Pharmaceuticals Company Information Table 87. Regeneron Pharmaceuticals Business Overview Table 88. Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Product Portfolio Table 90. Regeneron Pharmaceuticals Recent Development Table 91. Merus Company Information Table 92. Merus Business Overview Table 93. Merus Bispecific Antibodies for Cancer Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Merus Bispecific Antibodies for Cancer Product Portfolio Table 95. Merus Recent Development Table 96. North America Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 97. North America Bispecific Antibodies for Cancer Sales by Country (2021-2026) & (k units) Table 98. North America Bispecific Antibodies for Cancer Sales Market Share by Country (2021-2026) Table 99. North America Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032) & (k units) Table 100. North America Bispecific Antibodies for Cancer Sales Market Share Forecast by Country (2027-2032) Table 101. North America Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. North America Bispecific Antibodies for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 103. North America Bispecific Antibodies for Cancer Market Share by Country (2021-2026) Table 104. North America Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. North America Bispecific Antibodies for Cancer Market Share Forecast by Country (2027-2032) Table 106. Europe Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 107. Europe Bispecific Antibodies for Cancer Sales by Country (2021-2026) & (k units) Table 108. Europe Bispecific Antibodies for Cancer Sales Market Share by Country (2021-2026) Table 109. Europe Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032) & (k units) Table 110. Europe Bispecific Antibodies for Cancer Sales Market Share Forecast by Country (2027-2032) Table 111. Europe Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Europe Bispecific Antibodies for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 113. Europe Bispecific Antibodies for Cancer Market Share by Country (2021-2026) Table 114. Europe Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Europe Bispecific Antibodies for Cancer Market Share Forecast by Country (2027-2032) Table 116. Asia-Pacific Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 117. Asia-Pacific Bispecific Antibodies for Cancer Sales by Country (2021-2026) & (k units) Table 118. Asia-Pacific Bispecific Antibodies for Cancer Sales Market Share by Country (2021-2026) Table 119. Asia-Pacific Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032) & (k units) Table 120. Asia-Pacific Bispecific Antibodies for Cancer Sales Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific Bispecific Antibodies for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 123. Asia-Pacific Bispecific Antibodies for Cancer Market Share by Country (2021-2026) Table 124. Asia-Pacific Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Asia-Pacific Bispecific Antibodies for Cancer Market Share Forecast by Country (2027-2032) Table 126. Latin America Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 127. Latin America Bispecific Antibodies for Cancer Sales by Country (2021-2026) & (k units) Table 128. Latin America Bispecific Antibodies for Cancer Sales Market Share by Country (2021-2026) Table 129. Latin America Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032) & (k units) Table 130. Latin America Bispecific Antibodies for Cancer Sales Market Share Forecast by Country (2027-2032) Table 131. Latin America Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Latin America Bispecific Antibodies for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 133. Latin America Bispecific Antibodies for Cancer Market Share by Country (2021-2026) Table 134. Latin America Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Latin America Bispecific Antibodies for Cancer Market Share Forecast by Country (2027-2032) Table 136. Middle East and Africa Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 137. Middle East and Africa Bispecific Antibodies for Cancer Sales by Country (2021-2026) & (k units) Table 138. Middle East and Africa Bispecific Antibodies for Cancer Sales Market Share by Country (2021-2026) Table 139. Middle East and Africa Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032) & (k units) Table 140. Middle East and Africa Bispecific Antibodies for Cancer Sales Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa Bispecific Antibodies for Cancer Market Size by Country (2021-2026) & (US$ Million) Table 143. Middle East and Africa Bispecific Antibodies for Cancer Market Share by Country (2021-2026) Table 144. Middle East and Africa Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Middle East and Africa Bispecific Antibodies for Cancer Market Share Forecast by Country (2027-2032) Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Bispecific Antibodies for Cancer Distributors List Table 149. Bispecific Antibodies for Cancer Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Bispecific Antibodies for Cancer Image Figure 2. Global Bispecific Antibodies for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bispecific Antibodies for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Bispecific Antibodies for Cancer Sales (2021-2032) & (k units) Figure 5. CD19/CD3 Image Figure 6. Global CD19/CD3 Sales YoY Growth (2021-2032) & (k units) Figure 7. CD30/CD16A Image Figure 8. Global CD30/CD16A Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Bispecific Antibodies for Cancer Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Bispecific Antibodies for Cancer Market Share by Type 2025 VS 2032 Figure 11. North America Bispecific Antibodies for Cancer Sales Market Share in Volume by Type in 2025 Figure 12. North America Bispecific Antibodies for Cancer Sales Market Share in Value by Type in 2025 Figure 13. Europe Bispecific Antibodies for Cancer Sales Market Share in Volume by Type in 2025 Figure 14. Europe Bispecific Antibodies for Cancer Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Bispecific Antibodies for Cancer Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Bispecific Antibodies for Cancer Sales Market Share in Value by Type in 2025 Figure 17. Latin America Bispecific Antibodies for Cancer Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Bispecific Antibodies for Cancer Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Bispecific Antibodies for Cancer Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Bispecific Antibodies for Cancer Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Bispecific Antibodies for Cancer Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 25. Pharmaceutical Companies Image Figure 26. Global Pharmaceutical Companies Sales YoY Growth (2021-2032) & (k units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Bispecific Antibodies for Cancer Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Bispecific Antibodies for Cancer Market Share by Application 2025 VS 2032 Figure 31. North America Bispecific Antibodies for Cancer Sales Market Share in Volume by Application in 2025 Figure 32. North America Bispecific Antibodies for Cancer Sales Market Share in Value by Application in 2025 Figure 33. Europe Bispecific Antibodies for Cancer Sales Market Share in Volume by Application in 2025 Figure 34. Europe Bispecific Antibodies for Cancer Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Bispecific Antibodies for Cancer Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Bispecific Antibodies for Cancer Sales Market Share in Value by Application in 2025 Figure 37. Latin America Bispecific Antibodies for Cancer Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Bispecific Antibodies for Cancer Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Bispecific Antibodies for Cancer Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Bispecific Antibodies for Cancer Sales Market Share in Value by Application in 2025 Figure 41. North America Bispecific Antibodies for Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Bispecific Antibodies for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Bispecific Antibodies for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Bispecific Antibodies for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Bispecific Antibodies for Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Bispecific Antibodies for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Bispecific Antibodies for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Bispecific Antibodies for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Bispecific Antibodies for Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Bispecific Antibodies for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Bispecific Antibodies for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Bispecific Antibodies for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Bispecific Antibodies for Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Bispecific Antibodies for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Bispecific Antibodies for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Bispecific Antibodies for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Bispecific Antibodies for Cancer Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Bispecific Antibodies for Cancer Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Bispecific Antibodies for Cancer Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Bispecific Antibodies for Cancer Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Bispecific Antibodies for Cancer Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Bispecific Antibodies for Cancer Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • CD19/CD3
  • CD30/CD16A
Applications
  • Hospital
  • Pharmaceutical Companies
  • Other
Companies covered
  • Ben Kang Biopharmaceutical (Shenzhen)
  • Astella Pharma
  • Amgen
  • Regeneron Pharmaceuticals
  • Merus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bispecific Antibodies for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Bispecific Antibodies for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Bispecific Antibodies for Cancer Market by Type
  6. 1.3.1 CD19/CD3
  7. 1.3.2 CD30/CD16A
  8. 1.4 Global Bispecific Antibodies for Cancer Market Size by Type
  9. 1.4.1 Global Bispecific Antibodies for Cancer Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Bispecific Antibodies for Cancer Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Bispecific Antibodies for Cancer Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Bispecific Antibodies for Cancer Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Bispecific Antibodies for Cancer Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Bispecific Antibodies for Cancer Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Bispecific Antibodies for Cancer Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Bispecific Antibodies for Cancer Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Bispecific Antibodies for Cancer Industry Trends
  2. 2.2 Bispecific Antibodies for Cancer Industry Drivers
  3. 2.3 Bispecific Antibodies for Cancer Industry Opportunities and Challenges
  4. 2.4 Bispecific Antibodies for Cancer Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Bispecific Antibodies for Cancer Revenue (2021-2026)
  2. 3.2 Global Top Players by Bispecific Antibodies for Cancer Sales (2021-2026)
  3. 3.3 Global Top Players by Bispecific Antibodies for Cancer Price (2021-2026)
  4. 3.4 Global Bispecific Antibodies for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Bispecific Antibodies for Cancer Major Company Production Sites & Headquarters
  6. 3.6 Global Bispecific Antibodies for Cancer Company, Product Type & Application
  7. 3.7 Global Bispecific Antibodies for Cancer Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Bispecific Antibodies for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Bispecific Antibodies for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Bispecific Antibodies for Cancer Tier 1, Tier 2, and Tier 3
4 Bispecific Antibodies for Cancer Regional Status and Outlook
  1. 4.1 Global Bispecific Antibodies for Cancer Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Bispecific Antibodies for Cancer Historic Market Size by Region
  3. 4.2.1 Global Bispecific Antibodies for Cancer Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Bispecific Antibodies for Cancer Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Bispecific Antibodies for Cancer Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Bispecific Antibodies for Cancer Forecasted Market Size by Region
  7. 4.3.1 Global Bispecific Antibodies for Cancer Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Bispecific Antibodies for Cancer Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Bispecific Antibodies for Cancer Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Bispecific Antibodies for Cancer by Application
  1. 5.1 Bispecific Antibodies for Cancer Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmaceutical Companies
  4. 5.1.3 Other
  5. 5.2 Global Bispecific Antibodies for Cancer Market Size by Application
  6. 5.2.1 Global Bispecific Antibodies for Cancer Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Bispecific Antibodies for Cancer Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Bispecific Antibodies for Cancer Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Bispecific Antibodies for Cancer Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Bispecific Antibodies for Cancer Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Bispecific Antibodies for Cancer Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Bispecific Antibodies for Cancer Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Bispecific Antibodies for Cancer Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Ben Kang Biopharmaceutical (Shenzhen)
  2. 6.1.1 Ben Kang Biopharmaceutical (Shenzhen) Company Information
  3. 6.1.2 Ben Kang Biopharmaceutical (Shenzhen) Business Overview
  4. 6.1.3 Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Product Portfolio
  6. 6.1.5 Ben Kang Biopharmaceutical (Shenzhen) Recent Developments
  7. 6.2 Astella Pharma
  8. 6.2.1 Astella Pharma Company Information
  9. 6.2.2 Astella Pharma Business Overview
  10. 6.2.3 Astella Pharma Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Astella Pharma Bispecific Antibodies for Cancer Product Portfolio
  12. 6.2.5 Astella Pharma Recent Developments
  13. 6.3 Amgen
  14. 6.3.1 Amgen Company Information
  15. 6.3.2 Amgen Business Overview
  16. 6.3.3 Amgen Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Amgen Bispecific Antibodies for Cancer Product Portfolio
  18. 6.3.5 Amgen Recent Developments
  19. 6.4 Regeneron Pharmaceuticals
  20. 6.4.1 Regeneron Pharmaceuticals Company Information
  21. 6.4.2 Regeneron Pharmaceuticals Business Overview
  22. 6.4.3 Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Product Portfolio
  24. 6.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 6.5 Merus
  26. 6.5.1 Merus Company Information
  27. 6.5.2 Merus Business Overview
  28. 6.5.3 Merus Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merus Bispecific Antibodies for Cancer Product Portfolio
  30. 6.5.5 Merus Recent Developments
7 North America by Country
  1. 7.1 North America Bispecific Antibodies for Cancer Sales by Country
  2. 7.1.1 North America Bispecific Antibodies for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Bispecific Antibodies for Cancer Sales by Country (2021-2026)
  4. 7.1.3 North America Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032)
  5. 7.2 North America Bispecific Antibodies for Cancer Market Size by Country
  6. 7.2.1 North America Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Bispecific Antibodies for Cancer Market Size by Country (2021-2026)
  8. 7.2.3 North America Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Bispecific Antibodies for Cancer Sales by Country
  2. 8.1.1 Europe Bispecific Antibodies for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Bispecific Antibodies for Cancer Sales by Country (2021-2026)
  4. 8.1.3 Europe Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Bispecific Antibodies for Cancer Market Size by Country
  6. 8.2.1 Europe Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Bispecific Antibodies for Cancer Market Size by Country (2021-2026)
  8. 8.2.3 Europe Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Bispecific Antibodies for Cancer Sales by Country
  2. 9.1.1 Asia-Pacific Bispecific Antibodies for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Bispecific Antibodies for Cancer Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Bispecific Antibodies for Cancer Market Size by Country
  6. 9.2.1 Asia-Pacific Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Bispecific Antibodies for Cancer Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Bispecific Antibodies for Cancer Sales by Country
  2. 10.1.1 South America Bispecific Antibodies for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Bispecific Antibodies for Cancer Sales by Country (2021-2026)
  4. 10.1.3 South America Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032)
  5. 10.2 South America Bispecific Antibodies for Cancer Market Size by Country
  6. 10.2.1 South America Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Bispecific Antibodies for Cancer Market Size by Country (2021-2026)
  8. 10.2.3 South America Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Bispecific Antibodies for Cancer Sales by Country
  2. 11.1.1 Middle East and Africa Bispecific Antibodies for Cancer Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Bispecific Antibodies for Cancer Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Bispecific Antibodies for Cancer Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Bispecific Antibodies for Cancer Market Size by Country
  6. 11.2.1 Middle East and Africa Bispecific Antibodies for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Bispecific Antibodies for Cancer Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Bispecific Antibodies for Cancer Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Bispecific Antibodies for Cancer Value Chain Analysis
  2. 12.1.1 Bispecific Antibodies for Cancer Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Bispecific Antibodies for Cancer Production Mode & Process
  7. 12.2 Bispecific Antibodies for Cancer Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Bispecific Antibodies for Cancer Distributors
  10. 12.2.3 Bispecific Antibodies for Cancer Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst